Skip to content
This site uses cookies. By continuing to browse, you agree to the use of cookies. You can change your settings or learn more here.
OK
#Open journalism No news is bad news

Your contributions will help us continue to deliver the stories that are important to you

Support The Journal
Image: Pharmaceutical factory image via Shutterstock

Pharmaceutical firm announces €44m investment in Waterford plant

The biotechnology campus produces products for patients living with rare genetic diseases.
Feb 12th 2013, 7:30 PM 13,989 29

PHARMACEUTICAL COMPANY SANOFI announced today that it will invest €44 million in the Genzyme biotechnology campus in Co Waterford.

More than 500 people are employed at Genzyme Waterford, which produces products for patients living with rare genetic diseases, kidney disease and cholesterol management requirements that are shipped to more than 70 countries around the world.

The investment will increase the site’s range of products by adding the filling of Sanofi’s insulin glargine product which is the number one insulin brand worldwide.

Sanofi acquired Genzyme almost two years ago and the company said today it has been “continually impressed with the record of achievement” at the Waterford site.

Visiting the site today, Minister for Jobs, Enterprise and Innovation, Richard Bruton said this investment, which comes on top of a €150m investment little more than a year ago, will “ensure that this facility can produce the company’s latest product and provides an indication of the Waterford site’s strategic value”.

Read: 500 new jobs announced for Dublin and Galway>

Send a tip to the author

Michelle Hennessy

COMMENTS (29)

    Back to top